Oral News and Research

RSS

Lumena Pharmaceuticals initiates LUM001 clinical program in children with ALGS

Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the initiation of a global clinical program to evaluate its drug candidate LUM001 in children with Alagille syndrome. The first patient has been dosed in the IMAGO Phase II study being conducted in the U.K., and enrollment of pediatric patients is expected to begin later this year in the ITCH Phase II study in the U.S.

26 Sep 2013

Use of feeding tubes in OPC cancer patients treated with IMPT decreased by 50%

A new study from researchers at The University of Texas MD Anderson Proton Therapy Center found that the use of feeding tubes in oropharyngeal carcinoma cancer patients treated with intensity modulated proton therapy decreased by more than 50 percent compared to patients treated with intensity modulated radiation therapy.

26 Sep 2013

Ten health care innovations could save lives of mothers and children

Ten health care innovations, if brought to scale immediately in low-resource countries, could have the potential to save the lives of some 1.2 million mothers and children in 2015.

26 Sep 2013

MIT engineers develop nanoparticles that deliver cancer vaccines to lungs

Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, gastrointestinal tract and reproductive tract. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces.

26 Sep 2013

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today that it has been awarded a contract valued at up to $6.4 million by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

25 Sep 2013

Janssen signs license agreement with PATH for early development HIV-1 medicine rilpivirine

Janssen R&D Ireland announced today it has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 medicine rilpivirine in a long-acting injection (depot formulation) as potential pre-exposure prophylaxis against HIV infection.

25 Sep 2013

Johns Hopkins receives $7.3M contract to reduce ventilator-associated pneumonia

The Johns Hopkins Armstrong Institute for Patient Safety and Quality has been awarded a three-year, $7.3 million contract from the Agency for Healthcare Research & Quality to bring its proven checklist for reducing ventilator-associated pneumonia — the most lethal of all hospital-acquired infections — to hospitals nationwide.

25 Sep 2013

Researchers blame HPV for increased number of young adults with oropharyngeal cancer

The human papillomavirus (HPV) may be to blame for the alarming increase of young adults with oropharyngeal cancer, according to researchers from Henry Ford Hospital in Detroit.

25 Sep 2013

Quartette tablets now available in U.S. for prevention of pregnancy

Teva Women's Health, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the recently approved Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets are now available via prescription in the U.S. for the prevention of pregnancy.

24 Sep 2013

Abbvie, Galapagos Ink Up To $405M CF Collaboration

...

24 Sep 2013

Dental caries show ‘unexpected’ relationship with head and neck cancer

People with dental caries have a reduced risk for developing head and neck squamous cell carcinoma, a large case-control study has found.

24 Sep 2013

PRSA-NCC presents PRR with 2013 Thoth Best in Show Award

The Public Relations Society of America, National Capital Chapter, presented PRR with its 2013 Thoth Best in Show Award Wednesday, the evening's top honor for Washington D.C.-area industry professionals.

21 Sep 2013

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent.

21 Sep 2013

Specialty asthma care no benefit to adherence in underserved children

Results of a study of underserved children with asthma in the USA suggest that they may be losing out on the benefits of specialty care.

20 Sep 2013

Swallow therapy combats post-radiotherapy dysphagia

Swallowing exercises can help to minimize the risk for dysphagia in patients undergoing radiotherapy for head and neck cancer, a case study suggests.

20 Sep 2013

Hormone replacement therapy formulations may cause different risks for stroke, heart attack

Post-menopausal women whose doctors prescribe hormone replacement therapy for severe hot flashes and other menopause symptoms may want to consider taking low doses of Food and Drug Administration-approved bioidentical forms of estrogen or getting their hormones via a transdermal patch.

20 Sep 2013

Orbeshield Earns Soligenix Up To $26.3M From BARDA

...

19 Sep 2013

ASTRO to honor Atlanta resident and cancer survivor with 2013 Survivor Circle Award

The American Society for Radiation Oncology has selected Atlanta resident and cancer survivor Sherri Graves Smith to receive the 2013 Survivor Circle Award.

19 Sep 2013

Postpartum sexuality: an interview with Dr Sari van Anders, University of Michigan, Ann Arbor

Research on postpartum seems to have focused on birth mothers for good reason: women (and, of course, some transmen) are the ones who carry a pregnancy and give birth, and the postpartum is conceptualized as “following birth”.

19 Sep 2013

Federal judge passes consent order against Shamrock Medical for distributing mislabeled drugs

The U.S. Food and Drug Administration announced today that federal judge Algenon L. Marbley of the Southern District of Ohio has approved a consent decree of permanent injunction against Shamrock Medical Solutions Group, LLC, of Lewis Center, Ohio, and four of its corporate officers and employees for continued drug manufacturing and labeling violations that resulted in the distribution of mislabeled drugs.

19 Sep 2013

Oral News and Research

Lumena Pharmaceuticals initiates LUM001 clinical program in children with ALGS

Use of feeding tubes in OPC cancer patients treated with IMPT decreased by 50%

Ten health care innovations could save lives of mothers and children

MIT engineers develop nanoparticles that deliver cancer vaccines to lungs

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

Janssen signs license agreement with PATH for early development HIV-1 medicine rilpivirine

Johns Hopkins receives $7.3M contract to reduce ventilator-associated pneumonia

Researchers blame HPV for increased number of young adults with oropharyngeal cancer

Quartette tablets now available in U.S. for prevention of pregnancy

Abbvie, Galapagos Ink Up To $405M CF Collaboration

Dental caries show ‘unexpected’ relationship with head and neck cancer

PRSA-NCC presents PRR with 2013 Thoth Best in Show Award

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Specialty asthma care no benefit to adherence in underserved children

Swallow therapy combats post-radiotherapy dysphagia

Hormone replacement therapy formulations may cause different risks for stroke, heart attack

Orbeshield Earns Soligenix Up To $26.3M From BARDA

ASTRO to honor Atlanta resident and cancer survivor with 2013 Survivor Circle Award

Postpartum sexuality: an interview with Dr Sari van Anders, University of Michigan, Ann Arbor

Federal judge passes consent order against Shamrock Medical for distributing mislabeled drugs

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News